Publication | Closed Access

Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass

Bone DiseaseZoledronic AcidBone HealthRapid OnsetLow Bone MassMenopauseBone DensityMetabolic Bone DiseaseMedicineOsteoporosisWomen's Health